ArticleFrontiers in immunology2025
Novel RNA-methylase HNRNPC promotes gastric cancer tumorigenesis by triggering the lactate-induced ferroptosis resistance.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.Oncogene · 2026Review
- The evolving landscape of the Warburg effect in gastric cancer: From molecular mechanisms to targeted therapy.Clinical and translational medicine · 2026Review
- New Functions of Mitochondrial Dysfunction in Gastric Cancer: From Molecular Processes to Potential Treatments.International journal of molecular sciences · 2026Review
- Mechanism and therapeutic prospects of ferroptosis regulation through m6A in cancer.Frontiers in cell and developmental biology · 2026Review
- Integration of network toxicology and transcriptomics reveals the potential regulatory role of the 'Arecoline/4-NQO-AKT1-m6A factor' axis in the development of OSCC.Frontiers in oncology · 2026Article
- HNRNPC reprograms cancer metabolism to drive acquired chemoresistance in colorectal cancer by repressing of Nrf2/SLC7A11-dependent ferroptosis.Cell communication and signaling : CCS · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence gradually indicates that lactate and iron-induced cell death plays important role in gastric cancer (GC) progression. Here, this study focused on the effect of ferroptosis-related N Methods: The ferroptosis-related characteristic and lactate were tested by the kits. The in vivo mice animal assay was performed by subcutaneous xenotransplantation. The glycolysis-related analysis was performed by extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) analysis. Results: The elevated Heterogeneous Nuclear Ribonucleoprotein C (HNRNPC) expression positively fortified the aerobic glycolysis and lactate accumulation in GC. The exogenous lactate accelerated the proliferation, oxaliplatin resistance and aerobic glycolysis in GC that inhibited by HNRNPC silencing. Moreover, HNRNPC silencing up-regulated the iron concentration accumulation and ferroptosis, and the exogenous lactate and ferrostatin-1 (Fer-1, ferroptosis specific inhibitor) co-administration reduced the iron concentration. Mechanistically, MCT1 was identified as the downstream target of HNRNPC, and HNRNPC targeted MCT1 to fortify the lactate accumulation, thereby accelerating the ferroptosis resistance in GC. Conclusions: Overall, these findings revealed the novel role of ferroptosis-related HNRNPC on GC lactate accumulation and lactate-induced tumorigenesis in GC tumor microenvironment. The data revealed the importance of HNRNPC for lactate metabolism in GC tumor microenvironment, as well as the synergistic effect of HNRNPC on lactate-induced ferroptosis resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.